Advertisement

Topics

AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study

2014-07-24 14:06:31 | BioPortfolio

Summary

This is a multicentre post-marketing prospective study to evaluate performance and clinical outcomes of AMIIStem primary hip system.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Osteoarthritis

Intervention

AMIStem Hip System

Location

Uniklinik Balgrist
Zurich
Surrey
Switzerland
8008

Status

Recruiting

Source

Medacta International SA

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-24T14:06:31-0400

Clinical Trials [841 Associated Clinical Trials listed on BioPortfolio]

AMIStem-H Radiographic Analysis

Total hip replacement (THP) is widely used for hip osteoarthritis treatment. Surgeons are constantly looking to improve all aspects related to this procedure weather is improvement of impl...

AMIStem-H Radological Assessment

The purpose of this study is to evaluate radiological performance of the cementless femoral stem AMIStem H at 1 and 5-year follow-up. All the patients operated at the investigational site...

The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.

The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (5, 10, and 20 mg) in comparison to placebo transdermal system and ...

Safety and Efficacy of the Buprenorphine Transdermal System in Subjects With Mod-to-Sev Osteoarthritis of Hip or Knee

The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (5, 10 and 20 mg) in comparison to placebo transdermal system in su...

Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Mod-to-Sev Osteoarthritis Pain.

The objective of this study is to assess the safety and efficacy of the buprenorphine transdermal system (5, 10, and 20 mg) in comparison to placebo transdermal system in subjects with mod...

PubMed Articles [8678 Associated PubMed Articles listed on BioPortfolio]

Biomechanical Response to Osteoarthritis Pain Treatment May Impair Long Term Efficacy.

Pain has an important physiologic role and acts with and/or stimulates motor system adaptations to protect tissue from threats of damage. While clinically beneficial, removing the protective pain resp...

Relation of meniscus pathology to prevalence and worsening of patellofemoral joint osteoarthritis: The multicenter osteoarthritis study.

To determine the relationship of meniscal damage to magnetic resonance imaging (MRI) features of compartment-specific patellofemoral joint (PFJ) osteoarthritis (OA) at baseline and 2 years later.

Can Osteoarthritis Predict Mortality?

Osteoarthritis is the most common musculoskeletal condition. Due to the aging population and rising obesity worldwide, the projected increase in osteoarthritis is expected to be substantial. Since ost...

Response to Letter to the Editor: 'Subchondral tibial bone texture predicts the incidence of radiographic knee osteoarthritis: data from the Osteoarthritis Initiative: Methodological issues'.

An osteoarthritis model of care should be a national priority for New Zealand.

Osteoarthritis is highly prevalent, disabling and costly to the person and the community. The burden of this chronic condition is predicted to increase dramatically over the coming decades. Healthcare...

Medical and Biotech [MESH] Definitions

An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.

Viscoelastic solutions that are injected into JOINTS in order to alleviate symptoms of joint-related disorders such as OSTEOARTHRITIS.

A condition caused by degenerative arthritis (see OSTEOARTHRITIS) of the METATARSOPHALANGEAL JOINT of the great toe and characterized by pain and limited dorsiflexion, but relatively unrestricted plantar flexion.

A pyrazole derivative and selective CYCLOOXYGENASE 2 INHIBITOR that is used to treat symptoms associated with RHEUMATOID ARTHRITIS; OSTEOARTHRITIS and JUVENILE ARTHRITIS, as well as the management of ACUTE PAIN.

Noninflammatory degenerative disease of the hip joint which usually appears in late middle or old age. It is characterized by growth or maturational disturbances in the femoral neck and head, as well as acetabular dysplasia. A dominant symptom is pain on weight-bearing or motion.

More From BioPortfolio on "AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial